# Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

> **NCT00764634** · PHASE2 · COMPLETED · sponsor: **DynPort Vaccine Company LLC, A GDIT Company** · enrollment: 440 (actual)

## Conditions studied

- Botulism Vaccine

## Interventions

- **BIOLOGICAL:** Placebo (USP sterile saline for injection)
- **BIOLOGICAL:** rBV A/B-40 vaccine
- **BIOLOGICAL:** Placebo (USP sterile saline for injection)
- **BIOLOGICAL:** rBV A/B-40 vaccine

## Key facts

- **NCT ID:** NCT00764634
- **Lead sponsor:** DynPort Vaccine Company LLC, A GDIT Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-03
- **Final completion:** 2010-12
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2011-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00764634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00764634, "Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00764634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*